Voriconazole-associated salt-losing nephropathy.
A 74-year-old man was diagnosed with nephrotic syndrome due to focal segmental glomerulosclerosis, and steroid therapy was initiated. Subsequently, he was affected by deep mycosis, and hence, voriconazole (VRCZ) was administered. On the 16th day, he was transferred to our hospital because of somnolence and malaise. His systolic blood pressure was approximately 80 mmHg, and he showed decreased skin turgor, indicating volume depletion. Laboratory analysis revealed hyponatremia and liver dysfunction. Discontinuation of VRCZ and drip infusion of normal saline improved the consciousness disorder, hyponatremia, and liver dysfunction. The levels of antidiuretic hormone (ADH) and plasma renin activity were elevated. This patient showed high excreted urine sodium, despite volume depletion and low serum osmolality. Therefore, this patient was diagnosed with salt-losing nephropathy (SLN). SLN should be considered for treatment of VRCZ-associated hyponatremia, together with syndrome of inappropriate secretion of ADH.
Teranishi
Junya
J
Department of Nephrology, Osaka Medical College, Takatsuki, Japan.
Nagatoya
Katsuyuki
K
Kakita
Tomoko
T
Yamauchi
Yoko
Y
Matsuda
Hirohisa
H
Mori
Tatsuhiko
T
Inoue
Toru
T
D000368:Aged; D000935:Antifungal Agents / Q000009:adverse effects*; D015415:Biomarkers / Q000097:blood; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology / Q000503:physiopathology; D005440:Fluid Therapy; D006801:Humans; D007010:Hyponatremia / Q000097:blood / Q000139:chemically induced* / Q000503:physiopathology / Q000628:therapy; D007674:Kidney Diseases / Q000097:blood / Q000139:chemically induced* / Q000503:physiopathology / Q000628:therapy; D008099:Liver / Q000187:drug effects / Q000503:physiopathology; D008297:Male; D009481:Neurophysins / Q000097:blood; D011498:Protein Precursors / Q000097:blood; D011743:Pyrimidines / Q000009:adverse effects*; D012083:Renin / Q000097:blood; D012964:Sodium / Q000097:blood; D012965:Sodium Chloride / Q000008:administration & dosage; D013997:Time Factors; D016896:Treatment Outcome; D014230:Triazoles / Q000009:adverse effects*; D014667:Vasopressins / Q000097:blood; D065819:Voriconazole; D014882:Water-Electrolyte Balance / Q000187:drug effects*
C438657:AVP protein, human; D000935:Antifungal Agents; D015415:Biomarkers; D009481:Neurophysins; D011498:Protein Precursors; D011743:Pyrimidines; D014230:Triazoles; D014667:Vasopressins; D012965:Sodium Chloride; D012964:Sodium; D012083:Renin; D065819:Voriconazole